Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 68

1.

Efficacy, safety and impact on antimicrobial resistance of duration and dose of amoxicillin treatment for young children with Community-Acquired Pneumonia: a protocol for a randomIsed controlled Trial (CAP-IT).

Lyttle MD, Bielicki JA, Barratt S, Dunn D, Finn A, Harper L, Jackson P, Powell CVE, Roland D, Stohr W, Sturgeon K, Wan M, Little P, Faust SN, Robotham J, Hay AD, Gibb DM, Sharland M; PERUKI, GAPRUKI and the CAP-IT trial team.

BMJ Open. 2019 May 22;9(5):e029875. doi: 10.1136/bmjopen-2019-029875.

2.

Multi-arm, multi-stage randomised controlled trials for evaluating therapeutic HIV cure interventions.

Moore CL, Stöhr W, Crook AM, Richert L, Leliévre JD, Pantaleo G, García F, Vella S, Lévy Y, Thiébaut R, McCormack S.

Lancet HIV. 2019 May;6(5):e334-e340. doi: 10.1016/S2352-3018(19)30082-7.

PMID:
31047670
3.

Optimizing the immunogenicity of HIV prime-boost DNA-MVA-rgp140/GLA vaccines in a phase II randomized factorial trial design.

Viegas EO, Kroidl A, Munseri PJ, Missanga M, Nilsson C, Tembe N, Bauer A, Joachim A, Joseph S, Mann P, Geldmacher C, Fleck S, Stöhr W, Scarlatti G, Aboud S, Bakari M, Maboko L, Hoelscher M, Wahren B, Robb ML, Weber J, McCormack S, Biberfeld G, Jani IV, Sandström E, Lyamuya E; TaMoVac study group.

PLoS One. 2018 Nov 29;13(11):e0206838. doi: 10.1371/journal.pone.0206838. eCollection 2018.

4.

Patient Self-Reported Adherence to Ritonavir-Boosted Darunavir Combined With Either Raltegravir or Tenofovir Disoproxil Fumarate/Emtricitabine in the NEAT001/ANRS143 Trial.

Ammassari A, Stöhr W, Antinori A, Molina JM, Schwimmer C, Domingo P, Thalme A, Di Pietro M, Wallet C, Pozniak A, Richert L, Raffi F; NEAT001/ANRS143 Trial Study Group.

J Acquir Immune Defic Syndr. 2018 Dec 1;79(4):481-490. doi: 10.1097/QAI.0000000000001834.

5.

Virological remission after antiretroviral therapy interruption in female African HIV seroconverters.

Gossez M, Martin GE, Pace M, Ramjee G, Premraj A, Kaleebu P, Rees H, Inshaw J, Stöhr W, Meyerowitz J, Hopkins E, Jones M, Hurst J, Porter K, Babiker A, Fidler S, Frater J; SPARTAC Trial Investigators.

AIDS. 2019 Feb 1;33(2):185-197. doi: 10.1097/QAD.0000000000002044.

6.

Patient Self-Reported Adherence to Ritonavir-Boosted Darunavir Combined with Either Raltegravir or Tenofovir Disoproxil Fumarate /Emtricitabine in the Neat 001/Anrs 143 Trial.

Ammassari A, Stöhr W, Antinori A, Molina JM, Schwimmer C, Domingo P, Thalme A, Di Pietro M, Wallet C, Pozniak A, Richert L, Raffi F; and the NEAT 001/ANRS 143 Trial Study Group.

J Acquir Immune Defic Syndr. 2018 Aug 27. doi: 10.1097/QAI.0000000000001834. [Epub ahead of print]

PMID:
30153121
7.

Brain Perfusion, Regional Volumes, and Cognitive Function in Human Immunodeficiency Virus-positive Patients Treated With Protease Inhibitor Monotherapy.

Haddow LJ, Godi C, Sokolska M, Cardoso MJ, Oliver R, Winston A, Stöhr W, Clarke A, Chen F, Williams IG, Johnson M, Paton N, Arenas-Pinto A, Golay X, Jäger HR.

Clin Infect Dis. 2019 Mar 5;68(6):1031-1040. doi: 10.1093/cid/ciy617.

PMID:
30084882
8.

A study on the dynamics of temporary HIV treatment to assess the controversial outcomes of clinical trials: An in-silico approach.

Mancini E, Quax R, De Luca A, Fidler S, Stohr W, Sloot PMA.

PLoS One. 2018 Jul 18;13(7):e0200892. doi: 10.1371/journal.pone.0200892. eCollection 2018.

9.

Next generation sequencing of HIV-1 protease in the PIVOT trial of protease inhibitor monotherapy.

Dunn DT, Stöhr W, Arenas-Pinto A, Tostevin A, Mbisa JL, Paton NI; or the Protease Inhibitor Monotherapy Versus Ongoing Triple Therapy PIVOT Trial Team.

J Clin Virol. 2018 Apr;101:63-65. doi: 10.1016/j.jcv.2018.02.003. Epub 2018 Feb 5.

10.

Evaluation of cerebrospinal fluid virological escape in patients on long-term protease inhibitor monotherapy.

Arenas-Pinto A, Stöhr W, Clarke A, Williams I, Beeching NJ, Minton J, Lee V, Paton NI; Protease Inhibitor monotherapy Versus Ongoing Triple therapy (PIVOT) CNS sub-study Team.

Antivir Ther. 2017;22(6):535-538. doi: 10.3851/IMP3146. Epub 2017 Feb 24.

11.

Post-treatment control or treated controllers? Viral remission in treated and untreated primary HIV infection.

Martin GE, Gossez M, Williams JP, Stöhr W, Meyerowitz J, Leitman EM, Goulder P, Porter K, Fidler S, Frater J; the SPARTAC Trial Investigators.

AIDS. 2017 Feb 20;31(4):477-484. doi: 10.1097/QAD.0000000000001382.

12.

Factors associated with virological rebound in HIV-infected patients receiving protease inhibitor monotherapy.

Stöhr W, Dunn DT, Arenas-Pinto A, Orkin C, Clarke A, Williams I, Johnson M, Beeching NJ, Wilkins E, Sanders K, Paton NI; Protease Inhibitor Monotherapy Versus Ongoing Triple Therapy (PIVOT) Trial Team.

AIDS. 2016 Nov 13;30(17):2617-2624.

PMID:
27456983
13.

Changes in Cognitive Function Over 96 Weeks in Naive Patients Randomized to Darunavir-Ritonavir Plus Either Raltegravir or Tenofovir-Emtricitabine: A Substudy of the NEAT001/ANRS143 Trial.

Winston A, Stöhr W, Antinori A, Amieva H, Perré P, De Wit S, Reynes J, Gompels M, dʼArminio Monforte A, Gatell JM, Grarup J, Pozniak A, Babiker A, Raffi F, Richert L; NEAT 001ANRS 143 Study Group.

J Acquir Immune Defic Syndr. 2017 Feb 1;74(2):185-192. doi: 10.1097/QAI.0000000000001189.

PMID:
27749603
14.

Comparative Immunogenicity of HIV-1 gp140 Vaccine Delivered by Parenteral, and Mucosal Routes in Female Volunteers; MUCOVAC2, A Randomized Two Centre Study.

Cosgrove CA, Lacey CJ, Cope AV, Bartolf A, Morris G, Yan C, Baden S, Cole T, Carter D, Brodnicki E, Shen X, Joseph S, DeRosa SC, Peng L, Yu X, Ferrari G, Seaman M, Montefiori DC, Frahm N, Tomaras GD, Stöhr W, McCormack S, Shattock RJ.

PLoS One. 2016 May 9;11(5):e0152038. doi: 10.1371/journal.pone.0152038. eCollection 2016.

15.

Neurocognitive Function and Neuroimaging Markers in Virologically Suppressed HIV-positive Patients Randomized to Ritonavir-boosted Protease Inhibitor Monotherapy or Standard Combination ART: A Cross-sectional Substudy From the PIVOT Trial.

Arenas-Pinto A, Stöhr W, Jäger HR, Haddow L, Clarke A, Johnson M, Chen F, Winston A, Godi C, Thust S, Trombin R, Cairns J, Solanky BS, Golay X, Paton NI; PIVOT Neurocognitive sub-study Team.

Clin Infect Dis. 2016 Jul 15;63(2):257-64. doi: 10.1093/cid/ciw279. Epub 2016 May 3.

16.
17.

Cost Effectiveness of Protease Inhibitor Monotherapy Versus Standard Triple Therapy in the Long-Term Management of HIV Patients: Analysis Using Evidence from the PIVOT Trial.

Oddershede L, Walker S, Stöhr W, Dunn DT, Arenas-Pinto A, Paton NI, Sculpher M; Protease Inhibitor monotherapy Versus Ongoing Triple therapy (PIVOT) Trial Team.

Pharmacoeconomics. 2016 Aug;34(8):795-804. doi: 10.1007/s40273-016-0396-x.

PMID:
26966125
18.

Host and disease factors are associated with cognitive function in European HIV-infected adults prior to initiation of antiretroviral therapy.

Winston A, Stöhr W, Antinori A, Arenas-Pinto A, Llibre JM, Amieva H, Cabié A, Williams I, Di Perri G, Tellez MJ, Rockstroh J, Babiker A, Pozniak A, Raffi F, Richert L; NEAT 001/Agence Nationale de Recherche sur le SIDA (ANRS) 143 Study Group.

HIV Med. 2016 Jun;17(6):471-8. doi: 10.1111/hiv.12344. Epub 2015 Nov 26.

19.

Protease inhibitor monotherapy for long-term management of HIV infection: a randomised, controlled, open-label, non-inferiority trial.

Paton NI, Stöhr W, Arenas-Pinto A, Fisher M, Williams I, Johnson M, Orkin C, Chen F, Lee V, Winston A, Gompels M, Fox J, Scott K, Dunn DT; Protease Inhibitor Monotherapy Versus Ongoing Triple Therapy (PIVOT) Trial Team.

Lancet HIV. 2015 Oct;2(10):e417-26. doi: 10.1016/S2352-3018(15)00176-9. Epub 2015 Sep 14.

20.

Priming with a simplified intradermal HIV-1 DNA vaccine regimen followed by boosting with recombinant HIV-1 MVA vaccine is safe and immunogenic: a phase IIa randomized clinical trial.

Munseri PJ, Kroidl A, Nilsson C, Joachim A, Geldmacher C, Mann P, Moshiro C, Aboud S, Lyamuya E, Maboko L, Missanga M, Kaluwa B, Mfinanga S, Podola L, Bauer A, Godoy-Ramirez K, Marovich M, Moss B, Hoelscher M, Gotch F, Stöhr W, Stout R, McCormack S, Wahren B, Mhalu F, Robb ML, Biberfeld G, Sandström E, Bakari M.

PLoS One. 2015 Apr 15;10(4):e0119629. doi: 10.1371/journal.pone.0119629. eCollection 2015.

21.

The effect of short-course antiretroviral therapy initiated in primary HIV-1 infection on interleukin-6 and D-dimer levels.

Hamlyn E, Stöhr W, Cooper DA, Fisher M, Tambussi G, Schechter M, Miro JM, Vanobberghen F, Babiker A, Weber J, Mcclure M, Porter K, Fidler S; SPARTAC Investigators.

AIDS. 2015 Jul 17;29(11):1355-61. doi: 10.1097/QAD.0000000000000675.

22.

Cost-effectiveness analysis of protease inhibitor monotherapy vs. ongoing triple-therapy in the long-term management of HIV patients.

Oddershede L, Walker S, Paton N, Stöhr W, Dunn D, Sculpher M.

J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19498. doi: 10.7448/IAS.17.4.19498. eCollection 2014.

23.

Cost-Effectiveness Analysis of Protease Inhibitor Monotherapy Verse Ongoing Triple-Therapy in the Long-Term Management of HIV Patients.

Oddershede L, Walker S, Paton N, Stöhr W, Dunn D, Sculpher MJ.

Value Health. 2014 Nov;17(7):A683. doi: 10.1016/j.jval.2014.08.2550. Epub 2014 Oct 26. No abstract available.

24.

HIV-1 DNA predicts disease progression and post-treatment virological control.

Williams JP, Hurst J, Stöhr W, Robinson N, Brown H, Fisher M, Kinloch S, Cooper D, Schechter M, Tambussi G, Fidler S, Carrington M, Babiker A, Weber J, Koelsch KK, Kelleher AD, Phillips RE, Frater J; SPARTACTrial Investigators.

Elife. 2014 Sep 12;3:e03821. doi: 10.7554/eLife.03821.

25.

Neurocognitive function in HIV-infected patients: comparison of two methods to define impairment.

Arenas-Pinto A, Winston A, Stöhr W, Day J, Wiggins R, Quah SP, Ainsworth J, Fleck S, Dunn D, Accoroni A, Paton NI; PIVOT Trial Team.

PLoS One. 2014 Jul 31;9(7):e103498. doi: 10.1371/journal.pone.0103498. eCollection 2014.

26.

Interleukin-6 and D-dimer levels at seroconversion as predictors of HIV-1 disease progression.

Hamlyn E, Fidler S, Stöhr W, Cooper DA, Tambussi G, Schechter M, Miro JM, Mcclure M, Weber J, Babiker A, Porter K; SPARTAC Trial Investigators.

AIDS. 2014 Mar 27;28(6):869-74. doi: 10.1097/QAD.0000000000000155.

PMID:
24300544
27.

Duration of HIV-1 viral suppression on cessation of antiretroviral therapy in primary infection correlates with time on therapy.

Stöhr W, Fidler S, McClure M, Weber J, Cooper D, Ramjee G, Kaleebu P, Tambussi G, Schechter M, Babiker A, Phillips RE, Porter K, Frater J.

PLoS One. 2013 Oct 25;8(10):e78287. doi: 10.1371/journal.pone.0078287. eCollection 2013.

28.

Neurocognitive function in HIV infected patients on antiretroviral therapy.

Winston A, Arenas-Pinto A, Stöhr W, Fisher M, Orkin CM, Aderogba K, De Burgh-Thomas A, O'Farrell N, Lacey CJ, Leen C, Dunn D, Paton NI; PIVOT Trial Team.

PLoS One. 2013 Apr 30;8(4):e61949. doi: 10.1371/journal.pone.0061949. Print 2013.

29.

Effects of age on antiretroviral plasma drug concentration in HIV-infected subjects undergoing routine therapeutic drug monitoring.

Winston A, Jose S, Gibbons S, Back D, Stohr W, Post F, Fisher M, Gazzard B, Nelson M, Gilson R, Orkin C, Johnson M, Palfreeman A, Chadwick D, Leen C, Schwenk A, Anderson J, Gompels M, Dunn D, Khoo S, Sabin C; UK Collaborative HIV Cohort Study.

J Antimicrob Chemother. 2013 Jun;68(6):1354-9. doi: 10.1093/jac/dkt029. Epub 2013 Feb 23.

PMID:
23435690
30.

Glomerular dysfunction and associated risk factors over 4-5 years following antiretroviral therapy initiation in Africa.

Stöhr W, Reid A, Walker AS, Ssali F, Munderi P, Mambule I, Kityo C, Grosskurth H, Gilks CF, Gibb DM, Hakim J; DART Trial Team.

Antivir Ther. 2011;16(7):1011-20. doi: 10.3851/IMP1832.

PMID:
22024517
31.

Antibody levels against tetanus and diphtheria after polychemotherapy for childhood sarcoma: a report from the Late Effects Surveillance System.

Paulides M, Stöhr W, Laws HJ, Graf N, Lakomek M, Berthold F, Schmitt K, Niggli F, Jürgens H, Bielack S, Koscielniak E, Klingebiel T, Langer T.

Vaccine. 2011 Feb 11;29(8):1565-8. doi: 10.1016/j.vaccine.2010.12.084. Epub 2011 Jan 8.

PMID:
21219980
32.

Immunity against tetanus and diphtheria after childhood sarcoma treatment.

Paulides M, Stöhr W, Laws HJ, Graf N, Lakomek M, Berthold F, Schmitt K, Niggli F, Jürgens H, Bielack S, Koscielniak E, Klingebiel T, Langer T.

Klin Padiatr. 2010 May;222(3):196. doi: 10.1055/s-0030-1249609. Epub 2010 May 31. No abstract available.

PMID:
20514629
33.

Effect of tenofovir disoproxil fumarate on risk of renal abnormality in HIV-1-infected children on antiretroviral therapy: a nested case-control study.

Judd A, Boyd KL, Stöhr W, Dunn D, Butler K, Lyall H, Sharland M, Shingadia D, Riordan A, Gibb DM.

AIDS. 2010 Feb 20;24(4):525-34. doi: 10.1097/QAD.0b013e3283333680.

PMID:
20139752
34.

Factors influencing lopinavir and atazanavir plasma concentration.

Stöhr W, Back D, Dunn D, Sabin C, Winston A, Gilson R, Pillay D, Hill T, Ainsworth J, Gazzard B, Leen C, Bansi L, Fisher M, Orkin C, Anderson J, Johnson M, Easterbrook P, Gibbons S, Khoo S; UK CHIC Steering Committee.

J Antimicrob Chemother. 2010 Jan;65(1):129-37. doi: 10.1093/jac/dkp408.

35.

Active visfatin is elevated in serum of maintenance haemodialysis patients and correlates inversely with circulating HDL cholesterol.

Nüsken KD, Petrasch M, Rauh M, Stöhr W, Nüsken E, Schneider H, Dötsch J.

Nephrol Dial Transplant. 2009 Sep;24(9):2832-8. doi: 10.1093/ndt/gfp178. Epub 2009 Apr 23.

PMID:
19389865
36.

Estimating glomerular filtration rate in HIV-infected adults in Africa: comparison of Cockcroft-Gault and Modification of Diet in Renal Disease formulae.

Stöhr W, Walker AS, Munderi P, Tugume S, Gilks CF, Darbyshire JH, Hakim J; DART Trial.

Antivir Ther. 2008;13(6):761-70.

PMID:
18839777
37.

Factors influencing efavirenz and nevirapine plasma concentration: effect of ethnicity, weight and co-medication.

Stöhr W, Back D, Dunn D, Sabin C, Winston A, Gilson R, Pillay D, Hill T, Ainsworth J, Pozniak A, Leen C, Bansi L, Fisher M, Orkin C, Anderson J, Johnson M, Easterbrook P, Gibbons S, Khoo S; Liverpool TDM Database; UK CHIC Study.

Antivir Ther. 2008;13(5):675-85.

PMID:
18771051
38.

EV02: a Phase I trial to compare the safety and immunogenicity of HIV DNA-C prime-NYVAC-C boost to NYVAC-C alone.

McCormack S, Stöhr W, Barber T, Bart PA, Harari A, Moog C, Ciuffreda D, Cellerai C, Cowen M, Gamboni R, Burnet S, Legg K, Brodnicki E, Wolf H, Wagner R, Heeney J, Frachette MJ, Tartaglia J, Babiker A, Pantaleo G, Weber J.

Vaccine. 2008 Jun 13;26(25):3162-74. doi: 10.1016/j.vaccine.2008.02.072. Epub 2008 May 6.

PMID:
18502003
39.

Severe renal dysfunction and risk factors associated with renal impairment in HIV-infected adults in Africa initiating antiretroviral therapy.

Reid A, Stöhr W, Walker AS, Williams IG, Kityo C, Hughes P, Kambugu A, Gilks CF, Mugyenyi P, Munderi P, Hakim J, Gibb DM; Development of Antiretroviral Therapy Trial.

Clin Infect Dis. 2008 Apr 15;46(8):1271-81. doi: 10.1086/533468.

PMID:
18444867
40.

An HIV-1 clade C DNA prime, NYVAC boost vaccine regimen induces reliable, polyfunctional, and long-lasting T cell responses.

Harari A, Bart PA, Stöhr W, Tapia G, Garcia M, Medjitna-Rais E, Burnet S, Cellerai C, Erlwein O, Barber T, Moog C, Liljestrom P, Wagner R, Wolf H, Kraehenbuhl JP, Esteban M, Heeney J, Frachette MJ, Tartaglia J, McCormack S, Babiker A, Weber J, Pantaleo G.

J Exp Med. 2008 Jan 21;205(1):63-77. doi: 10.1084/jem.20071331. Epub 2008 Jan 14.

41.

CD4 cell count and initiation of antiretroviral therapy: trends in seven UK centres, 1997-2003.

Stöhr W, Dunn D, Porter K, Hill T, Gazzard B, Walsh J, Gilson R, Easterbrook P, Fisher M, Johnson M, Delpech V, Phillips A, Sabin C; UK CHIC Study.

HIV Med. 2007 Apr;8(3):135-41.

42.
43.

Thyroid function in paediatric and young adult patients after sarcoma therapy: a report from the Late Effects Surveillance System.

Paulides M, Dörr HG, Stöhr W, Bielack S, Koscielniak E, Klingebiel T, Jürgens H, Bölling T, Willich N, Sauer R, Langer T, Beck JD; Late Effects Surveillance System.

Clin Endocrinol (Oxf). 2007 May;66(5):727-31. Epub 2007 Mar 23.

PMID:
17381483
44.

Prevalence, incidence and predictors of severe anaemia with zidovudine-containing regimens in African adults with HIV infection within the DART trial.

Ssali F, Stöhr W, Munderi P, Reid A, Walker AS, Gibb DM, Mugyenyi P, Kityo C, Grosskurth H, Hakim J, Byakwaga H, Katabira E, Darbyshire JH, Gilks CF; DART Trial Team.

Antivir Ther. 2006;11(6):741-9.

PMID:
17310818
45.

Growth impairment after ifosfamide-induced nephrotoxicity in children.

Stöhr W, Patzer L, Paulides M, Kremers A, Beck JD, Langer T, Rossi R.

Pediatr Blood Cancer. 2007 May;48(5):571-6.

PMID:
16755549
46.

Nephrotoxicity of cisplatin and carboplatin in sarcoma patients: a report from the late effects surveillance system.

Stöhr W, Paulides M, Bielack S, Jürgens H, Koscielniak E, Rossi R, Langer T, Beck JD.

Pediatr Blood Cancer. 2007 Feb;48(2):140-7.

PMID:
16724313
47.

Ifosfamide-induced nephrotoxicity in 593 sarcoma patients: a report from the Late Effects Surveillance System.

Stöhr W, Paulides M, Bielack S, Jürgens H, Treuner J, Rossi R, Langer T, Beck JD.

Pediatr Blood Cancer. 2007 Apr;48(4):447-52.

PMID:
16628552
48.

Hydrochlorothiazide in CLDN16 mutation.

Zimmermann B, Plank C, Konrad M, Stöhr W, Gravou-Apostolatou C, Rascher W, Dötsch J.

Nephrol Dial Transplant. 2006 Aug;21(8):2127-32. Epub 2006 Apr 4.

49.

Prospective evaluation of hepatitis B, C and HIV infections as possible sequelae of antineoplastic treatment in paediatric sarcoma patients: a report from the Late Effects Surveillance System.

Paulides M, Stöhr W, Bielack S, Jürgens H, Koscielniak E, Klingebiel T, Zimmermann R, Stachel D, Langer T, Beck JD.

Oncol Rep. 2006 Mar;15(3):687-91.

PMID:
16465431
50.

Prospective longitudinal evaluation of doxorubicin-induced cardiomyopathy in sarcoma patients: a report of the late effects surveillance system (LESS).

Paulides M, Kremers A, Stöhr W, Bielack S, Jürgens H, Treuner J, Beck JD, Langer T; German Late Effects Working Group in the Society of Pediatric Oncology and Haematology (GPOH).

Pediatr Blood Cancer. 2006 Apr;46(4):489-95.

PMID:
16333817

Supplemental Content

Support Center